To date, preclinical proofs of concept have been described for hCFPs with improved rationally designed inhibitor insensitive variants of the protease granzyme B and the RNase angiogenin in addition to other human cytoskeleton interfering proteins, such as the microtubule-associated protein tau, or death-associated protein kinases to treat various cancers [32, 33, 35–37]. Here, MAPT is linked to cancer.